AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 2, 2012, Pages 217-222

  Bostick, Brian ^a   Shin, Jin Hong ^a,b   Yue, Yongping ^a   Wasala, Nalinda B ^a   Lai, Yi ^a   Duan, Dongsheng ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

AAV; Dilated cardiomyopathy; Duchenne cardiomyopathy; Duchenne muscular dystrophy; Dystrophin; Gene therapy; Heart failure

Indexed keywords

DOBUTAMINE; DYSTROPHIN; MICRO DYSTROPHIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAM; END STAGE DUCHENNE MUSCULAR DYSTROPHY CARDIOMYOPATHY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HEART DEATH; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE FIBROSIS; LIFE EXPECTANCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL VEIN; TREATMENT RESPONSE; VEIN; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CARDIOMYOPATHIES; DEPENDOVIRUS; DYSTROPHIN; ENDOMYOCARDIAL FIBROSIS; FEMALE; GENE THERAPY; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84862906115     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.05.002     Document Type: Article

References (27)

1. Shin J.-H., Bostick B., Yue Y., Duan D. Duchenne cardiomyopathy gene therapy. Muscle gene therapy 2010, 141-162. Springer Science+Business Media, LLC, New York. D. Duan (Ed.).
2. Duan D. Challenges opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet Oct 15 2006, 15(Spec No 2):R253-R261.
3. Chamberlain J.S., Metzger J., Reyes M., Townsend D., Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007 Jul, 21(9):2195-2204.
4. Li D., Long C., Yue Y., Duan D. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice. Hum Mol Genet 2009 Apr 1, 18(7):1209-1220.
5. Bostick B., Yue Y., Duan D. Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy. Muscle Nerve 2010 Oct, 42(4):600-603.
6. Bostick B., Yue Y., Long C., Duan D. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008 Jan 4, 102(1):121-130.
7. Bostick B., Shin J.-H., Yue Y., Duan D. AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther 2011, 19(10):1826-1832.
8. Bostick B., Yue Y., Lai Y., Long C., Li D., Duan D. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008 Aug, 19(8):851-856.
9. Gregorevic P., Allen J.M., Minami E., Blankinship M.J., Haraguchi M., Meuse L., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006 Jul, 12(7):787-789.
10. Yue Y., Li Z., Harper S.Q., Davisson R.L., Chamberlain J.S., Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003 Sep 30, 108(13):1626-1632.
11. Shin J.H., Nitahara-Kasahara Y., Hayashita-Kinoh H., Ohshima-Hosoyama S., Kinoshita K., Chiyo T., et al. Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther 2011 Sep, 18(9):910-919.
12. Townsend D., Blankinship M.J., Allen J.M., Gregorevic P., Chamberlain J.S., Metzger J.M. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007 June, 15(6):1086-1092.
13. Harper S.Q., Hauser M.A., DelloRusso C., Duan D., Crawford R.W., Phelps S.F., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002, 8(3):253-261.
14. Yue Y., Liu M., Duan D. C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol Ther 2006 Jul, 14(1):79-87.
15. Morris G., Man N.T., Sewry C.A. Monitoring Duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies. Methods Mol Biol 2011, 709:39-61.
16. Bostick B., Yue Y., Long C., Marschalk N., Fine D.M., Chen J., et al. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther 2009 Feb, 17(2):253-261.
17. Bostick B., Yue Y., Duan D. Phenotyping cardiac gene therapy in mice. Methods Mol Biol 2011, 709:91-104.
18. Gyorke S., Stevens S.C., Terentyev D. Cardiac calsequestrin: quest inside the SR. J Physiol 2009 Jul 1, 587(Pt 13):3091-3094.
19. Periasamy M., Bhupathy P., Babu G.J. Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res 2008 Jan 15, 77(2):265-273.
20. Perloff J.K. Cardiac rhythm and conduction in Duchenne's muscular dystrophy: a prospective study of 20 patients. J Am Coll Cardiol 1984, 3(5):1263-1268.
21. Urasawa N., Wada M.R., Machida N., Yuasa K., Shimatsu Y., Wakao Y., et al. Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71. Circulation 2008 May 13, 117(19):2437-2448.
22. Bia B.L., Cassidy P.J., Young M.E., Rafael J.A., Leighton B., Davies K.E., et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999, 31(10):1857-1862.
23. Chu V., Otero J.M., Lopez O., Sullivan M.F., Morgan J.P., Amende I., et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002 Oct, 26(4):513-519.
24. Shin J.H., Bostick B., Yue Y., Hajjar R., Duan D. SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice. J Transl Med 2011, 9:132.
25. Gwathmey J.K., Yerevanian A.I., Hajjar R.J. Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 2011 May, 50(5):803-812.
26. Jessup M., Greenberg B., Mancini D., Cappola T., Pauly D.F., Jaski B., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011 Jun 27, 124(3):304-313.
27. Lai Y., Duan D. Progress in gene therapy of dystrophic heart disease. Gene Ther Feb 9 2012, 10.1038/gt.2012.10.